Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Core Viewpoint - Apogee Therapeutics, Inc. has successfully closed a public offering of 5,750,000 shares at a price of $70.00 per share, raising approximately $403 million in gross proceeds before expenses [1]. Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, targeting conditions such as Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [5]. - The company's lead program, Zumilokibart (APG777), is aimed at treating Atopic Dermatitis, which is identified as a significant and under-penetrated market [5]. - Apogee's antibody programs are designed to enhance efficacy and dosing by utilizing advanced antibody engineering to optimize therapeutic properties [5]. Offering Details - The public offering included the full exercise of underwriters' option to purchase an additional 750,000 shares, indicating strong demand [1]. - Jefferies, TD Cowen, Stifel, and Guggenheim Securities served as joint book-running managers for the offering, with Wedbush PacGrow and BTIG acting as lead managers [2].